Nanobiotix (NBTX) announced the presentation of Part 1 data from the Johnson & Johnson-sponsored CONVERGE study, a randomized Phase 2 clinical trial evaluating the potential first-in-class Nanoradioenhancer JNJ-1900 (NBTXR3) for patients with stage III inoperable non-small cell lung cancer (NSCLC), at the 2026 European Society for Radiotherapy and Oncology Annual Meeting.
Early findings indicated that intratumoral and intranodal injection of JNJ-1900 (NBTXR3) is both feasible and safe for patients with stage III unresectable NSCLC. Importantly, initial efficacy responses observed in seven patients who completed the full treatment regimen—which included concurrent chemoradiotherapy, JNJ-1900 (NBTXR3), and consolidation with durvalumab—are encouraging.
Among these patients, the overall response rate (ORR) reached 85.7%, with six out of seven showing positive outcomes. The complete response rate (CRR) was 57.1%, with four patients achieving complete remission, while the disease control rate (DCR) was 100%, as all seven patients experienced disease stabilization or improvement. Notably, the absence of progressive disease and the deepening of responses over time suggest the potential for durable, long-term benefit.
NBTX closed Friday's regular trading at $51.50 or $3.57 or 6.48%.
For More Such Health News, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.